By Lina carolina 
The scientific community is abuzz with a groundbreaking discovery that has overturned decades of understanding regarding a protein long associated with stimulating red blood cell production. Erythropoietin (EPO), identified nearly 40 years ago for its critical role in hematopoiesis, has now been revealed to possess a surprising and potent function: dampening the immune system’s response to cancer. This unexpected dual role, unveiled through extensive research, offers a paradigm shift in how we approach cancer immunotherapy and opens new avenues for treating previously resistant tumors.
Unlocking Dormant Immune Responses in Liver Cancer
At the heart of this revelation is the work of researchers who have demonstrated that by blocking EPO’s activity, they could transform "cold" liver tumors—those characterized by an absence of cancer-fighting immune cells—into "hot" tumors brimming with immune activity. This transformation was not merely cosmetic; when combined with existing immunotherapy, the treatment led to the complete regression of existing liver tumors in a significant majority of laboratory mice. In a stark contrast to control groups that succumbed to the disease within weeks, treated animals not only survived but remained healthy for the duration of the experimental period.
"This is a fundamental breakthrough in our understanding of how the immune system is turned off and on in cancer," stated Edgar Engleman, MD, PhD, a distinguished professor of pathology and medicine and the senior author of the study. His palpable excitement underscores the magnitude of the findings, with a hopeful outlook for swift translation to human clinical trials. The lead author of the study, basic life research scientist David Kung-Chun Chiu, PhD, has been instrumental in developing and employing advanced genome editing techniques to construct precise mouse models of liver cancer, allowing for meticulous investigation into tumor development and treatment response.
A Long-Underestimated Player in Cancer’s Defense
The journey to this discovery has been a lengthy one, marked by years of meticulous experimentation and a significant recalibration of scientific perspective. While EPO’s role in stimulating red blood cell production has been well-established since its isolation in the early 1980s, its potential involvement in immune modulation within the tumor microenvironment remained largely unexplored until now.
The research team’s investigation began with a deeper dive into the established clinical observations surrounding EPO. As far back as 2007, the U.S. Food and Drug Administration (FDA) mandated a black box warning for EPO-based drugs, a cautionary measure stemming from research indicating that administering EPO to cancer patients experiencing anemia to boost red blood cell counts paradoxically accelerated tumor growth. This correlation was so pronounced that subsequent studies observed a direct relationship between higher levels of naturally occurring EPO and its receptor (EPOR) within tumors and poorer patient prognoses.
"Those old reports showed clearly that the more EPO or EPOR there was in tumors, the worse off the patients were," explained Dr. Engleman. "But the connection between EPO and cancer immunity was never made until now. In fact, it took a long time and a lot of experiments to convince us that EPO plays a fundamental role in blocking the immune response to cancer, because EPO is so well established as a red blood cell growth factor." This inherent bias, rooted in decades of established knowledge, made it challenging for researchers to consider EPO as anything other than a simple stimulator of red blood cells.
Unraveling the Mechanisms of Immune Evasion
The study utilized sophisticated mouse models of liver cancer, engineered to recapitulate specific genetic mutations, histological characteristics, and therapeutic responses seen in human liver cancers. These models were crucial for dissecting the complex interplay between tumor cells, the immune system, and the burgeoning role of EPO. Tumor formation was induced either by injecting DNA encoding cancer-associated proteins or by implanting liver cancer cells directly into the animals’ livers.
A primary focus of the research was the efficacy of a common class of immunotherapy drugs that target the PD-1 molecule on T cells. PD-1 is a critical checkpoint protein that cancer cells exploit to evade immune surveillance by suppressing T cell activity. Therapies like Keytruda, which block this interaction, have revolutionized treatment for certain cancers, including melanoma and some lung cancers. However, a significant challenge remains: many common cancers, such as liver, pancreas, colon, breast, and prostate cancers, are largely resistant to these therapies.
The researchers observed that certain genetic mutations in their mouse models led to the development of "cold" tumors, which were effectively invisible to the immune system. These tumors, lacking an adequate infiltration of T cells, showed no response to anti-PD-1 treatment. In stark contrast, tumors driven by other mutations developed into "hot" tumors, characterized by a dense population of T cells, and were highly susceptible to anti-PD-1 therapy, which then activated the T cells to mount an attack.
The Unexpected Link: Hypoxia, EPO, and Immune Suppression
A pivotal moment in the research came with the unexpected observation that these immune-resistant "cold" tumors exhibited significantly elevated levels of EPO compared to their "hot" counterparts. This finding pointed towards a potential environmental trigger within the tumor microenvironment. The prevailing hypothesis is that the oxygen-poor conditions—a phenomenon known as hypoxia—frequently found in cold tumors induce cancer cells to produce proteins that, in turn, ramp up EPO production. The rationale behind this cellular response is to stimulate the creation of more red blood cells to combat the low oxygen levels.
"Hypoxia in tumors has been studied for decades," Dr. Engleman noted. "It just didn’t dawn on anyone, including me, that EPO could be doing anything in this context other than serving as a red blood cell growth factor." This admission highlights the deeply ingrained understanding of EPO’s primary function and the conceptual leap required to consider its alternative roles.
To validate this burgeoning hypothesis, the researchers delved into extensive public databases, confirming a strong correlation between elevated EPO levels and poorer survival rates in patients with various cancers, including liver, kidney, breast, colon, and skin cancers. This correlation provided compelling external evidence supporting their in-vitro findings.
The team then conducted targeted experiments, manipulating the ability of tumor cells to produce EPO. The results were striking. When mutations that typically led to cold tumors were modified to prevent EPO production, these tumors transformed into hot tumors. Conversely, hot tumors that were previously eradicated by the immune system began to thrive when engineered to produce elevated levels of EPO.
The Macrophage Connection: EPO’s Immunosuppressive Signal
Further meticulous investigation elucidated the precise mechanism by which EPO exerts its immunosuppressive effects. In cold tumors, cancer cells secrete EPO, which then binds to receptors on the surface of immune cells known as macrophages. This binding prompts macrophages to adopt an immunosuppressive phenotype, actively repelling cancer-killing T cells and inhibiting their activity. This intricate crosstalk between tumor cells and macrophages, mediated by EPO, creates a formidable barrier to anti-cancer immunity.
The critical importance of this EPO-driven signaling pathway was unequivocally demonstrated when the researchers combined the blocking of EPO signaling with anti-PD-1 therapy. In mice with cold liver tumors, treatment with either control agents or anti-PD-1 alone resulted in mortality within eight weeks. However, when macrophages were engineered to be unable to produce the EPO receptor, 40% of the mice survived for 18 weeks, the experimental endpoint. Furthermore, when anti-PD-1 treatment was administered to mice lacking the EPO receptor on their macrophages, all animals survived for the entire duration of the experiment, showcasing a profound synergistic effect.
"It’s simple," Dr. Engleman asserted. "If you remove this EPO signaling, either by lowering the hormone levels or by blocking the receptors on the macrophages, you don’t just get a reduction in tumor growth, you get tumor regression along with sensitivity to anti-PD-1 treatment." This statement encapsulates the transformative potential of targeting the EPO pathway as a novel therapeutic strategy.
Implications for Human Cancers and Future Therapies
The implications of this discovery extend far beyond liver cancer. Given the strong indications of EPO’s similar role in various human cancers, researchers are actively designing treatments that target EPO signaling in a broader range of malignancies. Two primary therapeutic approaches are being considered:
-
Non-specific EPO Protein Targeting: This strategy involves directly reducing EPO levels in the body. While this might lead to anemia, a side effect manageable through supportive care, the potential benefit of a highly effective cancer therapy could outweigh this trade-off, according to Dr. Engleman’s speculation.
-
Selective Receptor Blockade: A more targeted approach involves specifically blocking the EPO receptors on the surface of immunosuppressive macrophages within the tumor microenvironment. This aims to disrupt the EPO-mediated signaling cascade without affecting EPO’s essential red blood cell-stimulating functions elsewhere in the body.
The research, a collaborative effort involving scientists from the New York Blood Center and the pharmaceutical company ImmunEdge Inc., was generously funded by grants from the National Institutes of Health. Dr. Chiu’s co-founding of ImmunEdge Inc., along with Dr. Engleman’s role as a founder, shareholder, and board member, and their shared status as inventors of related patents, underscores the strong commitment to translating these fundamental discoveries into tangible clinical applications.
"I continue to be amazed by this finding," Dr. Engleman concluded. "Not every tumor is going to respond in the same way, but I’m very optimistic that this discovery will lead to powerful new cancer therapies." This sentiment reflects the scientific community’s anticipation for the next chapter in cancer treatment, one that promises to harness the body’s own immune system more effectively by understanding and manipulating the subtle yet powerful signals that govern its response to malignant growth. The journey from a fundamental understanding of red blood cell production to a potent strategy for combating cancer marks a significant scientific milestone, offering renewed hope to patients worldwide.